°ÄÃÅÁùºÏ²Ê¿ª½±¼Ç¼

Phishing warning 01-May-2024
We are aware of phishing emails targeting speakers of events whose names appear on our events pages. If you are unsure if an email regarding event registration or accommodation has come from us please contact us and do not provide any credit card details or personal information.

Excellence in Pharmacovigilance: Clinical Trials and Post-Marketing

2 October 2017 08:00 - 6 October 2017 16:00, London, United Kingdom


Introduction
This five-day training course also includes highlights and updates on the pharmacovigilance legislation and the latest news on the international harmonisation and standardisation activities in pharmacovigilance.

For the five key topics as outlined below, the learning objectives also include the ability to:

• Describe the expedited and periodic ICSRs reporting requirements in clinical trials and
post-marketing including the medical evaluation
• Understand the process of audits and inspections in pharmacovigilance
• Understand the principles of signal management
• Describe the components of the risk management

Key Topics
• Definitions and Methods in Pharmacovigilance
• Regulatory Aspects in Pharmacovigilance and Practical Examples
• Diagnosis of Adverse Drug Reactions
• Signal Detection and Signal Management
- Modern Technologies and Social Media
• Risk Management

Who Will Attend
This course will benefit professionals with minimum 1-2 year experience in Pharmacovigilance or adjacent functions, for example, PV Officers, PV Specialists, PV Experts, PV Coordinators,
Heads/Directors/Managers of Regulatory Compliance, Quality or Safety departments.
Level: Intermediate

Useful links

Speakers
Venue
The Crystal

The Crystal, One Siemens Brothers Way, Royal Victoria Docks, London, E16 1GB, United Kingdom

Organised by
DIA EMEA
Contact information
Customer Contact Center
DIA EMEA
+41 61 225 5151
Contact us by email

Search
 
 
Showing all upcoming events
Start Date
End Date
Location
Subject area
Event type

Advertisement
Spotlight


E-mail Enquiry
*
*
*
*